Jason H Kim

US Patent:

20130190137, Jul 25, 2013

Filed:

Jan 22, 2013

Appl. No.:

13/747262

Inventors:

Jason Sung-Il Kim - Pflugerville TX, US
Lucy Kim - Pflugerville TX, US
Steven JUN - Pflugerville TX, US

International Classification:

A63B 5/11

US Classification:

482 29

Abstract:

An apparatus for children's playground with trampoline includes a trampoline surface, a trampoline base, a staircase, and a safety net. The trampoline base provides a foundation for the trampoline surface so that the trampoline surface can be connected to a trampoline frame of the trampoline base by coil springs. The trampoline base includes a pair of concave parameter edges and a pair of slope parameter edges. The pair of concave parameter edges and the pair of slope parameter edges provide uniquely shaped trampoline surface for the users of the playground apparatus. The staircase enables the users to access the trampoline surface, and the safety net provides a protective wall for the user so that the users are able to stay within the trampoline surface.

US Patent:

20220401568, Dec 22, 2022

Filed:

Aug 27, 2021

Appl. No.:

17/459133

Inventors:

- Austin TX, US
Erin Willert - Round Rock TX, US
Jason Kim - Austin TX, US

Assignee:

Molecular Templates, Inc. - Austin TX

International Classification:

A61K 47/64
C07K 16/28
C07K 16/30
A61K 47/68
C07K 16/32
C07K 14/25
A61K 39/12
A61K 39/00

Abstract:

The present invention provides cell-targeting molecules which can deliver a CD8+ T-cell epitope cargo to the MHC class I presentation pathway of the cell. The cell-targeting molecules of the invention can be used to deliver virtually any CD8+ T-cell epitope from an extracellular space to the MHC class I pathway of a target cell, which may be a malignant cell and/or non-immune cell. The target cell can then display on a cell-surface the delivered CD8+ T-cell epitope complexed with MHC I molecule. The cell-targeting molecules of the invention have uses which include the targeted labeling and/or killing of specific cell-types within a mixture of cell-types, including within a chordate, as well as the stimulation of beneficial immune responses. The cell-targeting molecules of the invention have uses, e.g., in the treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections.

US Patent:

20220354938, Nov 10, 2022

Filed:

Jun 29, 2022

Appl. No.:

17/852669

Inventors:

- Austin TX, US
Erin WILLERT - Round Rock TX, US
Sangeetha RAJAGOPALAN - Round Rock TX, US
Garrett Lee ROBINSON - Austin TX, US
Brigitte BRIESCHKE - Austin TX, US
Jason KIM - Austin TX, US

International Classification:

A61K 39/00
A61K 47/68
C07K 14/25

Abstract:

The present invention provides cell-targeting molecules which can deliver a CD8+ T-cell epitope cargo to the MHC class I presentation pathway of a target cell. The cell-targeting molecules of the invention can be used to deliver virtually any CD8+ T-cell epitope from an extracellular space to the MHC class I pathway of a target cell, which may be a malignant cell and/or non-immune cell. The target cell can then display on a cell-surface the delivered CD8+ T-cell epitope complexed with MHC I molecule. The cell-targeting molecules of the invention have uses which include the targeted labeling and/or killing of specific cell-types within a mixture of cell-types, including within a chordate, as well as the stimulation of beneficial immune responses. The cell-targeting molecules of the invention have uses, e.g., in the treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections.

US Patent:

20220267384, Aug 25, 2022

Filed:

May 2, 2022

Appl. No.:

17/734881

Inventors:

- Austin TX, US
Erin WILLERT - Round Rock TX, US
Jason KIM - Austin TX, US
Jack HIGGINS - Georgetown TX, US

International Classification:

C07K 14/245
C07K 16/28
C07K 16/32
C07K 16/30
A61K 49/00

Abstract:

The present invention provides proteins comprising binding regions for cell-type specific targeting, Shiga toxin effector regions derived from A Subunits of members of the Shiga toxin family for providing Shiga toxin effector functions (e.g. cellular internalization and cytotoxicity), and carboxy-terminal endoplasmic reticulum localization signal motifs. The presently disclosed proteins can comprise additional exogenous materials, such as, e.g., antigens, cytotoxic agents, and detection-promoting agents, and are capable of targeted delivery of these additional exogenous materials into the interiors of target cells. The proteins of the present invention have uses in methods such as, e.g., methods involving targeted killing of target cells, delivering exogenous materials into target cells, labeling subcellular compartments of target cells, and diagnosing and/or treating a variety of conditions including cancers, tumors, other growth abnormalities, immune disorders, and microbial infections.

US Patent:

20210394907, Dec 23, 2021

Filed:

Sep 2, 2021

Appl. No.:

17/465500

Inventors:

- Chicago IL, US
Jason B. Kim - Edmonds WA, US
Angela Natale - Seattle WA, US

Assignee:

The Boeing Company - Chicago IL

International Classification:

B64D 11/06
B64F 5/10

Abstract:

Provided are seat track fittings and methods for installing passenger seats in aircraft cabins using these seat track fittings such that the same seat can be installed on different types of seat tracks. A seat track fitting comprises a leg support, a pin, and a base interconnecting the leg support and pin. During the installation of the seat track fitting, the pin is inserted into an attachment opening of the seat track. The attachment opening is selected based on the desired position of a seat. A removable fastener then protrudes through the base of the seat track fitting and is inserted into another attachment opening of the seat track. The seat is then attached to the seat track fitting by inserting the stud end of the seat into the leg support of the seat track fitting and fixing the stud end within the leg support.

US Patent:

20210268085, Sep 2, 2021

Filed:

Apr 12, 2021

Appl. No.:

17/228579

Inventors:

- Austin TX, US
Erin WILLERT - Round Rock TX, US
Sangeetha RAJAGOPALAN - Round Rock TX, US
Garrett Lee ROBINSON - Austin TX, US
Brigitte BRIESCHKE - Austin TX, US
Jason KIM - Austin TX, US

Assignee:

Molecular Templates, Inc. - Austin TX

International Classification:

A61K 39/00
A61K 47/68
C07K 14/25

Abstract:

The present invention provides cell-targeting molecules which can deliver a CD8+ T-cell epitope cargo to the MHC class I presentation pathway of a target cell. The cell-targeting molecules of the invention can be used to deliver virtually any CD8+ T-cell epitope from an extracellular space to the MHC class I pathway of a target cell, which may be a malignant cell and/or non-immune cell. The target cell can then display on a cell-surface the delivered CD8+ T-cell epitope complexed with MHC I molecule. The cell-targeting molecules of the invention have uses which include the targeted labeling and/or killing of specific cell-types within a mixture of cell-types, including within a chordate, as well as the stimulation of beneficial immune responses. The cell-targeting molecules of the invention have uses, e.g., in the treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections.

US Patent:

20210138076, May 13, 2021

Filed:

Jul 25, 2016

Appl. No.:

15/747501

Inventors:

- Austin TX, US
Erin Willert - Round Rock TX, US
Jason Kim - Austin TX, US

Assignee:

Molecular Templates, Inc. - Austin TX

International Classification:

A61K 47/64
A61K 47/68
C07K 16/28
C07K 16/30
C07K 16/32

Abstract:

The present invention provides cell-targeting molecules which can deliver a CD8+ T-cell epitope cargo to the MHC class I presentation pathway of the cell. The cell-targeting molecules of the invention can be used to deliver virtually any CD8+ T-cell epitope from an extracellular space to the MHC class I pathway of a target cell, which may be a malignant cell and/or non-immune cell. The target cell can then display on a cell-surface the delivered CD8+ T-cell epitope complexed with MHC I molecule. The cell-targeting molecules of the invention have uses which include the targeted labeling and/or killing of specific cell-types within a mixture of cell-types, including within a chordate, as well as the stimulation of beneficial immune responses. The cell-targeting molecules of the invention have uses, e.g., in the treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections.

US Patent:

20210017512, Jan 21, 2021

Filed:

Sep 24, 2020

Appl. No.:

17/030657

Inventors:

- Austin TX, US
Erin WILLERT - Round Rock TX, US
Jack HIGGINS - Georgetown TX, US
Jason KIM - Austin TX, US

Assignee:

Molecular Templates, Inc. - Austin TX

International Classification:

C12N 9/24
C07K 14/245
C12N 9/10
C07K 14/25
C07K 14/74
C07K 14/705
C07K 16/08
C07K 16/10
C07K 16/18
C07K 16/20
C07K 16/28
C07K 16/30
C07K 16/32

Abstract:

The present invention provides protease-cleavage resistant molecules comprising Shiga toxin effector polypeptides capable of exhibiting potent, Shiga toxin functions (e.g. subcellular routing and cytotoxicity). The present invention also provides protease-cleavage resistant, cell-targeting molecules for targeting specific cell types, e.g., infected or malignant cells. Certain molecules of the present invention are cytotoxic, and certain cell-targeting molecules of the present invention may be used for the targeted killing of specific cell types and the treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections. Certain cell-targeting molecules of the invention exhibit improved, in vivo tolerability as compared to related cell-targeting molecules comprising protease-cleavage sensitive, wild-type, Shiga toxin effector polypeptides. The cell-targeting molecules of the invention can deliver additional materials, such as, e.g., antigens, cytotoxic agents, and detection-promoting agents, into the interiors of target cells.